Citation Impact
Citing Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Treatment of skeletal disease in breast cancer with clodronate
1991
Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer
1991
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
1999 Standout
Cancer to bone: a fatal attraction
2011 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Concurrent Assays of Circulating Bone Gla-Protein and Bone Alkaline Phosphatase: Effects of Sex, Age, and Metabolic Bone Disease*
1988
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
2004 Standout
Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin
1993
Role of endothelin-1 in osteoblastic bone metastases
2003
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1999 Standout
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
2001
The history, properties, and biological effects of cachectin
1988 StandoutNobel
Cancer Metastasis: Building a Framework
2006 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1–38) and salmon calcitonin in osteoporotic patients
1991
Treatment of Tumor-Induced Osteolysis by APD
1989
Vitamin D Deficiency
2007 Standout
AID Is Required for c-myc/IgH Chromosome Translocations In Vivo
2004 StandoutNobel
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
1993 Standout
Impracticability of Informed Consent in the Registry of the Canadian Stroke Network
2004 Standout
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy
2001
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
2003 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Osteoporosis: now and the future
2011 Standout
A multigenic program mediating breast cancer metastasis to bone
2003 Standout
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
1997 Standout
POEMS syndrome: A study of 25 cases and a review of the literature
1994
Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma
1994
Skeletal remodeling in health and disease
2007 Standout
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
1997 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
University of California/Davis Interdepartmental Conference on Gram-Negative Septicemia
1991 StandoutNobel
Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the bone
2001
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
2001 Standout
Wnt/β-Catenin Signaling and Disease
2012 Standout
Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement
2003 Standout
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
1998
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
2003
Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
1994
Emerging Biological Principles of Metastasis
2017 Standout
Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
1999
Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo
1995
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism
2005
Microenvironmental regulation of metastasis
2008 Standout
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption
1992
Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma
1993
Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma
1994
Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia
1992
Osteoclasts are required for bone tumors to grow and destroy bone
1998
Cellular changes in rat parathyroids provoked by progesterone and testosterone
1992
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Anabolic Actions of Parathyroid Hormone on Bone*
1993
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Mechanisms of Bone Metastasis
2004 Standout
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis
1990 Standout
Bisphosphonates
1991
Bisphosphonates—much more than only drugs for bone diseases
2019
Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the Skeleton
1998
The Histomorphometry of Bone in Primary Hyperparathyroidism: Preservation of Cancellous Bone Structure*
1990
Neoplastic development in plasma cells
2003
Relative in Vitro Efficacy of the Phosphate Binders Lanthanum Carbonate and Sevelamer Hydrochloride
2007 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The control of the false discovery rate in multiple testing under dependency
2001 Standout
Mechanisms of Bone Lesions in Multiple Myeloma
1992
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications
2001 Standout
Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease
1999
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
2002
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
1998
Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
1993
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2009
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
2002
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2008
Mechanisms of bone metastasis
1997
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*
2000 Standout
Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay
1992
Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma Cells
1987
Skeletal complications of malignancy
1997 Standout
Long-term fluoride therapy of postmenopausal osteoporosis
1986
Functional Significance of Cell Volume Regulatory Mechanisms
1998 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Bone metabolism and disease in chronic kidney disease
2003
Oral bisphosphonates
2000
The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair.
1996
Skeletal disease in primary hyperparathyroidism
1989
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease [see comments]
1995 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Bone destruction and hypercalcemia in plasma cell myeloma.
1986
A systematic review of the role of bisphosphonates in metastatic disease
2004
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
1995 Standout
Works of S Charhon being referenced
Bilateral fractures of femoral neck in patients with moderate renal failure receiving fluoride for spinal osteoporosis.
1983
Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple Myeloma
1982
[Chronic polyradiculitis with cutaneous and endocrine signs suggesting a plasmocytic dyscrasia to IgA (author's transl)].
1980
Evidence for a toxic effect of aluminum on osteoblasts: A histomorphometric study in hemodialysis patients with aplastic bone disease
1988
Effects of Parathyroid Hormone on Remodeling of Iliac Trabecular Bone Packets in Patients with Primary Hyperparathyroidism
1982
Skeletal Distribution and Biochemical Parameters of Paget's Disease
1987
[Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)].
1982
Long Term Effects of Dichloromethylene Diphosphonate in Paget's Disease of Bone
1982
Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome.
1984
[Treatment of hypercalcemia of myelomatous origin with intravenous diphosphonates].
1983
Deferoxamine-induced bone changes in haemodialysis patients: A histomorphometric study
1987
Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: The influence of human parathyroid fragment (hPTH 1-34) therapy
1981
Quantitative histology of myeloma‐induced bone changes
1982
Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy: Effects on biochemical parameters and bone histomorphometry
1987
Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia
1983
Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients
1985
Serum Bone Gla-Protein in Renal Osteodystrophy:Comparison with Bone Histomorphometry*
1986
Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
1985